Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 929248, 9 pages
http://dx.doi.org/10.1155/2014/929248
Research Article

Determination of Critical Parameters of Drug Substance Influencing Dissolution: A Case Study

1Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1/3, 612 42 Brno, Czech Republic
2Faculty of Chemistry, Brno University of Technology, Purkynova 464/118, 612 00 Brno, Czech Republic

Received 2 August 2014; Revised 25 August 2014; Accepted 27 August 2014; Published 15 September 2014

Academic Editor: Kin Tam

Copyright © 2014 Erika Bojnanska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Pharmaceutical Quality for the 21st Century—A Risk based Approach, Food and Drug Administration, 2007.
  2. “Guidance for industry: PAT—A framework for innovative pharmaceutical development, manufacturing and quality assurance,” Food and Drug Administration, 2004.
  3. L. X. Yu, “Pharmaceutical quality by design: product and process development, understanding, and control,” Pharmaceutical Research, vol. 25, no. 4, pp. 781–791, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. “ICH Guideline Q8(R2)—Pharmaceutical development,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2009.
  5. “ICH Guideline Q9—Quality risk management,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2005.
  6. “ICH guideline Q10—Pharmaceutical quality system,” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2008.
  7. “ICH Guideline Q11—Development and manufacture of drug substances (chemical entities and biotechnological/biological entities),” in Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2012.
  8. R. K. Varu and A. Khanna, “Opportunities and challenges to implementing Quality by Design approach in generic drug development,” Journal of Generic Medicines, vol. 7, no. 1, pp. 60–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. J. Purohit and K. V. Shah, “Quality by design (QbD): new parameter for quality improvement & pharmaceutical drug development,” Pharma Science Monitor, vol. 4, pp. 1–19, 2013. View at Google Scholar
  10. S. Brunauer, P. H. Emmett, and E. Teller, “Adsorption of gases in multimolecular layers,” Journal of the American Chemical Society, vol. 60, no. 2, pp. 309–319, 1938. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Yuan and T. R. Lee, “Contact angle and wetting properties,” in Surface Science Techniques, G. Bracco and B. Holst, Eds., vol. 51 of Springer Series in Surface Sciences, pp. 3–34, Springer, Berlin, Germany, 2013. View at Google Scholar
  12. W. B. Russel, D. A. Saville, and W. R. Schowalter, Colloidal Dispersions, Cambridge University Press, Cambridge, UK, 1989.
  13. J. Lyklema, Fundamentals of Interface and Colloid Science, vol. 2 of Solid-Liquid Interface, Academic Press, London, UK, 1995.
  14. A. Salis, M. Boström, L. Medda et al., “Measurements and theoretical interpretation of points of zero charge/potential of BSA protein,” Langmuir, vol. 27, no. 18, pp. 11597–11604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. R. Chu, E. Lee, S. H. Jeong, and E.-S. Park, “Effect of particle size on the dissolution behaviors of poorly water-soluble drugs,” Archives of Pharmacal Research, vol. 35, no. 7, pp. 1187–1195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. D. S. Phadke and J. L. Eichorst, “Evaluation of particle size distribution and specific surface area of magnesium stearate,” Drug Development and Industrial Pharmacy, vol. 17, no. 6, pp. 901–906, 1991. View at Publisher · View at Google Scholar · View at Scopus
  17. M. E. Aulton and K. Taylor, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, Churchill Livingstone/Elsevier, London, UK, 4th edition, 2013.
  18. P. Finholt, “Influence of formulation on dissolution rate,” in Dissolution Technology, L. J. Leeson and T. J. Catensen, Eds., p. 108, APHA, Washington, DC, USA, 1974. View at Google Scholar
  19. A. L. Behera, S. K. Sahoo, and S. V. Patil, “Enhancement of solubility: a pharmaceutical overview,” Der Pharmacia Lettre, vol. 2, pp. 310–318, 2010. View at Google Scholar
  20. L. V. Allen and H. C. Ansel, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Kluwer Academic Publishers, Baltimor, Md, USA, 10th edition, 2013.